CNTG Stock Overview
Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Centogene N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$1.98 |
| 52 Week Low | US$0.34 |
| Beta | -0.68 |
| 11 Month Change | 3.48% |
| 3 Month Change | -46.14% |
| 1 Year Change | -51.63% |
| 33 Year Change | -96.40% |
| 5 Year Change | n/a |
| Change since IPO | -97.24% |
Recent News & Updates
Recent updates
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Feb 16
Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks
Dec 21Centogene GAAP EPS of -€0.28, revenue of €10.32M
Jul 15Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?
Nov 25Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?
Jun 29Centogene reports Q1 results
Jun 16Centogene, Alector initiate EFRONT study in frontotemporal dementia
Jun 02Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting
May 26Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)
Apr 17What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?
Mar 05Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year
Jan 29Is Centogene (NASDAQ:CNTG) A Risky Investment?
Dec 18Centogene reports Q3 results
Dec 16Shareholder Returns
| CNTG | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 4.4% | -0.9% | 0.5% |
| 1Y | -51.6% | 2.7% | 23.9% |
Return vs Industry: CNTG underperformed the US Healthcare industry which returned 2.7% over the past year.
Return vs Market: CNTG underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| CNTG volatility | |
|---|---|
| CNTG Average Weekly Movement | 11.1% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CNTG's share price has been volatile over the past 3 months.
Volatility Over Time: CNTG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 384 | Kim Stratton | www.centogene.com |
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.
Centogene N.V. Fundamentals Summary
| CNTG fundamental statistics | |
|---|---|
| Market cap | US$11.22m |
| Earnings (TTM) | -US$37.99m |
| Revenue (TTM) | US$51.90m |
0.2x
P/S Ratio-0.3x
P/E RatioIs CNTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTG income statement (TTM) | |
|---|---|
| Revenue | €48.54m |
| Cost of Revenue | €30.84m |
| Gross Profit | €17.70m |
| Other Expenses | €53.23m |
| Earnings | -€35.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 36.46% |
| Net Profit Margin | -73.21% |
| Debt/Equity Ratio | -260.1% |
How did CNTG perform over the long term?
See historical performance and comparison